The clinical and radiological prognostic factors were investigated in 32 patients with newly diagnosed anaplastic oligodendroglioma treated by combined therapy using surgery, postoperative radiation therapy, and adjuvant chemotherapy between September 1994 and December 2002. Surgery aimed at total removal was followed by radiotherapy, and 3 weeks later by adjuvant chemotherapy repeated at 6-to 7-week intervals. Survival analysis showed that younger age, absence of preoperative headache, good postoperative Karnofsky Performance Status (KPS) score (AE80), and relatively small tumor volume (º50 cm 3 ) were predictors for longer survival in univariate analysis (p º 0.05). Age and good postoperative KPS score were independent prognostic factors in multivariate analysis (p º 0.05). Median survival was 58 months after diagnosis, and the 5-year survival rate was 49%.
Introduction
The term oligodendroglial tumor includes both oligodendroglioma and anaplastic oligodendroglioma according to the World Health Organization (WHO) classification of tumors. Oligodendroglial tumors account for about 3.2% of all central nervous system tumors, of which 28.2% are anaplastic oligodendrogliomas in Korea. 20) The survival of patients is affected by the tumor location, histological grade, age at surgery, extent of surgical removal, tumor size, postoperative Karnofsky Performance Status (KPS) score, and timing of radiation therapy, based on univariate or multivariate analysis. 5, 7, 11, 19, 24) However, these findings were not based on only cases of pure anaplastic oligodendroglioma, but on cases of both oligodendroglioma (WHO grade II) and anaplastic oligodendroglioma (WHO grade III). The addition of adjuvant chemotherapy to surgery and postoperative radiotherapy, using nitrosoureas, gives better results with increased long-term survival in patients with malignant glioma. 4, 12) The clinical and radiological prognostic factors in patients with newly diagnosed anaplastic oligodendroglioma treated by combined therapy are unclear, 12) although the prognostic factors of anaplastic oligodendroglioma, which is related by pathology, chromosome, and genes, are known. 3, 9, 10, 17) The present study investigated patients with newly diagnosed anaplastic oligodendroglioma treated by combined therapy with surgery, postoperative radiotherapy, and adjuvant chemotherapy to identify the clinical and radiological prognostic factors.
Materials and Methods

I. Patient population
We evaluated 526 consecutive cases of gliomas treated at the Samsung Medical Center from September 1994 to December 2002. Among them, all patients treated under a diagnosis of oligodendroglioma (WHO grade II) or anaplastic oligodendroglioma (WHO grade III) were reviewed. This study included the patients with histologicallyproven anaplastic oligodendroglioma treated by combined therapy. Secondary anaplastic oligodendroglioma (malignant transformation) was excluded, so only newly diagnosed anaplastic oligodendroglioma was included. The histological diagnosis was re-evaluated by two independent neuropathologists and graded according to the 2000 Prognostic Factors of Anaplastic Oligodendroglioma WHO classification. 13) Anaplastic oligoastrocytoma was identified if the tumor contained anaplastic features and geographically distinct astrocytic and oligodendroglial components, which were excluded. Cases of disagreement were re-reviewed by both pathologists until a consensus was reached.
II. Combined therapy
Combined therapy consisted of surgery, postoperative radiotherapy, and adjuvant chemotherapy, in that order. Surgery was performed at the authors' institution and the aim was complete tumor removal. Conventional external field radiation (1.8 Gy/day, 5 days/week, total dose 56-60 Gy) was initiated in the 3rd to 4th postoperative week. Chemotherapy was performed at the authors' institution. Three weeks after completing irradiation, patients began PCV chemotherapy (procarbazine, lomustine [CCNU] , vincristine) with the following schedule: CCNU, 110 mg/m 2 orally on day 1; procarbazine, 60 mg/m 2 orally on days 8 through 21; and vincristine, 1.4 mg/m 2 i.v. on days 8 and 29. The PCV chemotherapy was repeated at 6-to 7-week intervals for six courses or until tumor progression.
When the recurrent tumors were detected, reoperation was performed if the tumor was surgically accessible, and then PCV chemotherapy was repeated for four courses.
III. Clinical and radiological parameters
The date of diagnosis and date of death (or last known status) were recorded for all patients. The following factors were evaluated for prognostic significance: age at diagnosis, sex, duration of symptoms, headache, seizure, neurological deficit at diagnosis, KPS score, tumor location, cystic change, enhancement on magnetic resonance (MR) imaging, midline shift, brain edema, contralateral involvement, calcification on computed tomography (CT), tumor volume, and extent of resection.
The presence of headache was recorded as the initial symptom and any history. The presence of seizure was recorded as a history of epilepsy prior to diagnosis, and occurrence of seizure at any time before or after the diagnosis of anaplastic oligodendroglioma. The KPS score was examined 1 week after operation (postoperative and preradiotherapy). The extent of tumor removal was assessed on the postoperative enhanced T 1 -weighted MR image within 48 hours after surgery, and graded as gross total resection (no obvious residual tumor), subtotal resection (residual tumor º50%), or biopsy (residual tumor À50%). Subtotal resection and biopsy were grouped together as less than total resection for statistical evaluation. Tumor volume was calculated as an ellipse. The horizontal (X), vertical (Y), and height (Z) dimensions were obtained and then used in the formula (p/6)(XYZ) to find the volume. Tumor location was considered as the area or lobe in which the tumor was predominantly located. Other factors such as brain edema, calcification on CT, contralateral involvement, cystic change, enhancement, and midline shift were observed on the preoperative MR image.
IV. Statistical analyses
Statistical calculations used the commercially available SPSS 10.0 software package (SPSS, Chicago, Ill., U.S.A.). The end point of this study was overall survival as measured from the date of operation that confirmed the diagnosis of anaplastic oligodendroglioma to the last follow-up visit or death. Univariate analysis constructed probability curves according to the Kaplan-Meier method for the 22 variables for comparison by the log rank test. Variables with a p value of less than 0.05 in the univariate analysis were subsequently introduced into a multivariate stepwise proportional hazards regression analysis (Cox model) to identify the parameters independently associated with survival.
Results
I. Patient population
Thirty-two patients, 16 males and 16 females (median age 41.5 years), with confirmed newly diagnosed anaplastic oligodendroglioma were treated by combined therapy. Median patient follow up was 35.3 months. Median survival time from diagnosis was 58 months (Fig. 1) . The overall 5-year survival rate was 49.38%. At the last follow up, 12 patients had died of the disease.
II. Clinical prognostic factors
The clinical factors associated with survival according to univariate analysis are reported in Table 1 . Age at diagnosis (Fig. 2) , headache as initial symptom (Fig. 3) , and KPS score at 1 week postoperation (Fig. 4) were all statistically significant. Sex, duration of symptoms, seizure, and neurological deficit at diagnosis were not significant factors. Extent of resection and timing of radiotherapy were also not significant factors.
III. Radiological prognostic factors
The radiological factors associated with survival according to univariate analysis are reported in Table 2 . Small tumor volume (º50 cm 3 ) was predictive of better survival (Fig. 5) . Tumor location, cystic change, enhancement, midline shift, brain edema, contralateral involvement, and calcification were not significant factors.
IV. Multivariate analysis for survival
Age at diagnosis, headache, KPS score at 1 week postoperation, and tumor volume with corresponding p values of less than 0.05 in the univariate analysis were introduced into multivariate analysis. Age at diagnosis and KPS score at 1 week postoperation had statistical significance as independent prognostic variables (p ＝ 0.025, 0.047). Small tumor volume (º50 cm 3 ) showed a tendency for better survival, but did not achieve statistical significance (p ＝ 0.051). Absence of headache as the initial symptom was not identified as a statistically significant parameter.
Discussion
Combined loss of 1p and 19q is a statistically significant multivariate predictor of overall survival in patients with anaplastic oligodendrogliomas, and is also significantly associated with both chemosensitivity and longer recurrence-free survival after chemotherapy. 3) The phosphatase and tensin homolog deleted by the chromosome 10 (PTEN) alteration is associated with poor prognosis. 17) Recent evidence suggests that molecular genetic analysis may provide a more powerful method for separating anaplastic oligodendrogliomas into therapeutically and prognostically significant subgroups. However, the clinical and radiological prognostic factors are still important for predicting the survival of patients with anaplastic oligodendroglioma. These factors may very well provide information in addition to the new molecular methods.
I. Age
Age has been reported as the most important predictor of survival, which is related, not unexpectedly, to the natural history of glioma, as a high rate of malignant transformation, higher proliferation index, and larger tumor volume all occur with increasing age. 1, 2, 7, 19, 22) Several criteria have been used in the past to define``younger age'' (21, 7) 40, 9) 45, 22) 49, 19) and 50 years 12, 14) ). For this study, younger age was anything under 50 years because the goal was to identify the oldest patient with anaplastic oligodendroglioma. Age was a statistically significant parameter (univariate and multivariate) for longer survival in the present patients with newly diagnosed anaplastic oligodendroglioma treated by combined therapy. The prognostic importance has been reaffirmed by this study.
II. Headache
Seizure is well known to be a good prognostic factor for patients with glioma, whereas headache was generally known to be unrelated with better survival. 9, 22) Headache is a typical symptom of increased intracranial pressure (ICP). So we simply used headache as indirect evidence of preoperative increased ICP. Some authors showed that no preoperative increased ICP sign could be a good prognostic factor (univariate) in anaplastic oligodendroglioma patients. 11) The present analysis showed that absence of headache at diagnosis was a statistically significant parameter (univariate) for survival whereas seizure was not. We failed to find any evidence of how headache and seizure were correlated. These two parameters did not overlap. Headache might be related to tumor volume but we could not prove any relationship between these two parameters. Additionally, we could not categorize the type of headache. Although the reason is hard to explain, patients with headache might have had increased ICP before surgery and this could influence the survival of patients with newly diagnosed anaplastic oligodendroglioma treated by combined therapy.
III. KPS score at 1 week after operation
The current study suggests that KPS score is the most consistent predictor of survival in patients Prognostic Factors of Anaplastic Oligodendroglioma with anaplastic gliomas. 6, 8, 12, 21) There are many baselines for KPS score as a prognostic factor: preoperative, 11, 12) postoperative, 11, 18, 22) below 90, 12) below 80, 11, 21) and below 70. 22, 24) We chose KPS score at 1 week postoperation as the baseline because we wanted to investigate both postoperative and preradiotherapy KPS score. Scoring below 80 was a statistically significant prognostic (univariate and multivariate) parameter. The prognostic importance has been reaffirmed by this study.
IV. Tumor volume
There was no correlation between the preoperative tumor size and length of life in patients with malignant glioma, 16, 23) but smaller tumors (Ã4 cm) were associated with improved survival when compared with tumors in general. 7, 12) This study found that tumor volume (º50 cm 3 ) is a significant prognostic factor (univariate and tendency for better survival in multivariate analysis). Therefore, tumor volume is related to the prognosis for patients with newly diagnosed anaplastic oligodendroglioma treated by combined therapy.
V. Multivariate analysis and other known predictors
Age at diagnosis and KPS score at 1 week postoperation were independent predictors for better survival in patients with newly diagnosed anaplastic oligodendroglioma treated by combined therapy. This study failed to show any statistical significance for headache history and tumor volume which were associated with better survival in univariate analysis. However, small tumor volume (º50 cm 3 ) may constitute a favorable prognostic factor, even if this factor did not achieve statistical significance (p ＝ 0.051) in the multivariate analysis where the number of patients was small.
These investigations did not reveal the favorable survival association with frontal localization reported in some series. 5, 9, 15) Although gross total tumor removal had an effect on survival in patients with anaplastic oligodendroglioma, 12) our results could not show any prognostic significance of total removal in patients with newly diagnosed anaplastic oligodendroglioma treated by combined therapy.
This small and single institutional study identified younger age, absence of headache, good KPS score, and small tumor volume as clinical and radiological prognostic factors for good survival in patients with newly diagnosed anaplastic oligodendroglioma treated by combined therapy. Further studies with more patients, longer follow up, and combination with molecular analysis will provide more information about this rare disease.
